ClinicalTrials.gg
RecruitingNCT06273176RECMAPUpdated Feb 22, 2024

The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma

An observational study in Glioblastoma, IDH-wildtype, Glioblastoma and Glioblastoma Multiforme of Brain, sponsored by Erasmus Medical Center. Recruiting at 8 sites in 5 countries. Open to participants aged Up to 90 Years. Per ClinicalTrials.gov, last updated 2024-02-22.

Sponsored by Erasmus Medical Center · Observational

How we know

From the registry’s dates

  • Started Jan 2023; still recruiting 3 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
225
Ages
Up to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,303 studies in Glioblastoma with a site in United States — 194 open to participants now, 324 under way, 16 of them phase 3. Glioblastoma · United States.

Planned enrollment
20th of 79
225 · median 60
Started
2023
with 57 others
Observational
79 of 1,303
20 open now
Primary completion
2027-01
later than 111 of 322 live
Registered
1,126th of 1,303
by date

Among the 1,303 studies in Glioblastoma with a site in United States, this one is the 20th largest by planned enrollment of the 79 observational ones that give a count, is one of 58 that started in 2023, is one of 79 observational ones, reaches primary completion later than 111 of the 322 other live ones, and was the 1,126th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,303 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: Up to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,303 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous evidence suggests that these techniques are beneficial for maximum safe resection in newly diagnosed grade 2-4 astrocytoma, grade 2-3 oligodendroglioma, and recently, glioblastoma. However, their effects in recurrent glioblastoma are still poorly understood. The aim of this study, therefore, is to compare the effects of awake mapping and asleep mapping with no mapping in resections for recurrent glioblastoma.

This study is an international, multicenter, prospective 3-arm cohort study of observational nature. Recurrent glioblastoma patients will be operated with mapping or no mapping techniques with a 1:1 ratio. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months after surgery and 2) residual tumor volume of the contrast-enhancing and non-contrast-enhancing part as assessed by a neuroradiologist on postoperative contrast MRI scans. Secondary endpoints are: 1) overall survival (OS), 2) progression-free survival (PFS), 4) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.

The study will be carried out by the centers affiliated with the European and North American Consortium and Registry for Intraoperative Mapping (ENCRAM).

Read the detailed description

This is an international, multicenter, prospective, 3-arm cohort study. Eligible patients are operated with or without mapping techniques with a 1:1 ratio with a sequential computer-generated random number as subject ID. Patients with motor-eloquent tumors will be treated in all study arms, while speech-eloquent tumors will only be treated in either the awake mapping or no mapping arm. The RECMAP study is similar to the SAFE-trial24 (awake craniotomy versus craniotomy under general anesthesia for glioblastoma patients, NCT03861299) and is initiated by the same center, however, the presented study will be different in various ways: the RECMAP study (1) will be an observational, prospective cohort study, (2) will include asleep mapping as an additional treatment arm, (3) will evaluate the extent of resection of the non-contrast-enhancing part of the tumor as well, (4) only includes recurrent tumors (5) will include neurosurgical centers in the United States and is part of the ENCRAM Research Consortium18. The RECMAP study is also similar to the PROGRAM study25 (awake mapping versus asleep mapping versus no mapping for high-grade glioma patients, NCT04708171), with the difference that the RECMAP study includes recurrent tumors (while the PROGRAM study includes newly diagnosed tumors), and that the RECMAP study includes recurrent glioblastoma, while the PRGORAM study includes WHO grade 3 and 4 gliomas.

Study patients are operated with either awake mapping, asleep mapping or no mapping and will undergo evaluation at presentation (baseline) and during the follow-up period at 6 weeks, 3 months, and 6 months postoperatively. Motor function will be evaluated using the NIHSS (National Institute of Health Stroke Scale) and MRC (Medical Research Council) scales. Language function will be evaluated using a standard neurolinguistic test-battery consisting of the Aphasia Bedside Check (ABC), Shortened Token test, Verbal fluency, Picture description and Object naming. This neurolinguistic test-battery is the result of a consensus between the participating centers. Cognitive function will be assessed using the Montreal Cognitive Assessment (MOCA). Overall patient functioning with be assessed with the Karnofsky Performance Scale (KPS) and the ASA (American Society of Anesthesiologists) physical status classification system for comorbidities. Health-related quality of life (HRQoL) will be assessed with the EQ-5D questionnaire and the EORTC QLQ-C30 and EORTC QLQ-BN20 questionnaires. Overall survival and progression-free survival will be assessed. We expect to complete patient inclusion in 4 years. The estimated duration of the study, including follow-up, will be 5 years.

The primary study objective is to evaluate the safety and efficacy of resections with or without mapping techniques (neurological morbidity and residual CE and NCE tumor volume) in recurrent glioblastoma patients as expressed by NIHSS scores and volumetric data. Secondary study objectives are to study the overall survival (OS), progressive-free survival (PFS), health-related quality of life (HRQoL), and Serious Adverse Events (SAEs) after resections with or without mapping techniques as expressed by survival data, progression on follow up MRI scans based on the RANO criteria26 for tumor progression, quality of life questionnaires (EORTC QLQ C30, EORTC QLQ BN20, EQ-5D), and registration of SAEs.

Patients will be recruited from the neurosurgical or neurological outpatient clinic or through referral from general hospitals of the participating neurosurgical hospitals, located in Europe and the United States. The study is carried out by centers from the ENCRAM Consortium.

03

Conditions studied

  • Glioblastoma, IDH-wildtype
  • Glioblastoma
  • Glioblastoma Multiforme of Brain
  • Astrocytoma, Malignant
  • Brain Neoplasms
  • Brain Neoplasms, Adult, Malignant
  • Brain Neoplasms, Adult
  • Recurrent Adult Brain Tumor
  • Recurrent Glioblastoma

Keywords

  • Glioblastoma
  • Recurrent
  • Re-resection
  • Resection
  • Intraoperative mapping
  • Awake mapping
  • Awake craniotomy
  • Asleep mapping
  • Motor mapping
  • Language mapping
  • Overall survival
  • Progression-free survival
  • Neurological morbidity
  • Quality of life
  • Functional area
  • Eloquent
  • Extent of resection
  • Residual tumor volume
04

Who can participate

Ages eligible
Up to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with recurrent glioblastoma will be recruited from the neurosurgical or neurological outpatient clinic or through referral from general hospitals of the participating neurosurgical hospitals, located in Europe and the United States. The study is carried out by centers from the ENCRAM Consortium.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years and ≤90 years
  2. Tumor recurrence according to the RANO criteria of a previously diagnosed glioblastoma based on the WHO 2021 classification for glioma
  3. Tumors situated in or near eloquent areas; motor cortex, sensory cortex, subcortical pyramidal tract, speech areas or visual areas as indicated on MRI (Sawaya Grading II and II)19
  4. The tumor is suitable for resection (according to neurosurgeon)
  5. Written

Exclusion criteria

Exclusion Criteria:

  1. Tumors of the cerebellum, brainstem, or midline
  2. Multifocal contrast-enhancing lesions
  3. Medical reasons precluding MRI (e.g., pacemaker)
  4. Inability to give written
  5. Secondary high-grade glioma due to malignant transformation from low-grade glioma
  6. Clinical data unavailable for the newly diagnosed setting
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
225 participants (estimated)
Patient registry
No

Groups and cohorts

  • Awake mapping

    Awake mapping: Tumor resection with intraoperative awake motor or language mapping

    Procedure: Awake mapping under local anesthesia

  • Asleep mapping

    Asleep mapping: Tumor resection with intraoperative asleep motor mapping

    Procedure: Asleep mapping under general anesthesia

  • No mapping

    No mapping: Tumor resection without intraoperative mapping

    Procedure: Resection under general anesthesia without mapping

Interventions

  • ProcedureAwake mapping under local anesthesia

    During an awake craniotomy, the patient is awake and cooperative during the resection of the tumor while the surgeon uses electro(sub)cortical mapping to prevent damage to eloquent areas.

    Also known as: Awake craniotomy

  • ProcedureAsleep mapping under general anesthesia

    During asleep mapping under general anesthesia, the surgeon uses electro(sub)cortical mapping with evoked potentials (MEPs, SSEPs or continuous dynamic mapping) to prevent damage to eloquent areas.

    Also known as: Asleep motor mapping, Continous dynamic mapping, Evoked potentials

  • ProcedureResection under general anesthesia without mapping

    During resection under general anesthesia without mapping, the surgeon does not use any intraoperative stimulation mapping techniques to identify eloquent areas.

06

What researchers measure

Primary outcomes

  1. Residual volume

    Residual tumor volume of the contrast-enhancing and non-contrast enhancing part, as assessed by a neuroradiologist on postoperative MRI scan (T1 with contrast and FLAIR sequences) using manual or semi-automatic volumetric analyses (Brainlab Elements iPlan CMF Segmentation, Brainlab AG, Munich, Germany; or similar software)

    Time frame: Within 72 hours postoperatively

  2. Neurological morbidity at 6 weeks

    NIHSS deterioration of 1 point or more at 6 weeks after surgery

    Time frame: 6 weeks postoperatively

Secondary outcomes

  1. Overall survival

    Time from diagnosis to death from any cause.

    Time frame: Up to 5 years postoperatively

  2. Progression-free survival

    Time from diagnosis to disease progression (occurrence of a new tumor lesions with a volume greater than 0.175 cm3, or an increase in residual tumor volume of more than 25%) or death, whichever comes first

    Time frame: Up to 5 years postoperatively

  3. Onco-functional outcome (OFO)

    According to the OFO classification, consisting of the combination of presence/absence of functional deterioration with gross-total resection

    Time frame: 6 weeks postoperatively

  4. Serious Adverse Events

    Serious Adverse Events within 6 weeks postoperatively

    Time frame: 6 weeks postoperatively

  5. Neurological morbidity at 3 months

    NIHSS deterioration of 1 point or more at 3 months after surgery

    Time frame: 3 months postoperatively

  6. Neurological morbidity at 6 months

    NIHSS deterioration of 1 point or more at 6 months after surgery

    Time frame: 6 months postoperatively

  7. Overall functioning at 6 weeks

    KPS deterioration at 6 weeks after surgery

    Time frame: 6 weeks postoperatively

  8. Overall functioning at 3 months

    KPS deterioration at 3 months after surgery

    Time frame: 6 months postoperatively

  9. Overall functioning at 6 months

    KPS deterioration at 6 months after surgery

    Time frame: 6 months postoperatively

  10. Quality of life at 6 weeks (EORTC QLQ C30)

    Quality of life as assessed by the EORTC QLQ C30 questionnaire

    Time frame: 6 weeks postoperatively

  11. Quality of life at 3 months (EORTC QLQ C30)

    Quality of life as assessed by the EORTC QLQ C30 questionnaire

    Time frame: 3 months postoperatively

  12. Quality of life at 6 months (EORTC QLQ C30)

    Quality of life as assessed by the EORTC QLQ C30 questionnaire

    Time frame: 6 months postoperatively

  13. Quality of life at 6 weeks (EORTC QLQ BN20)

    Quality of life as assessed by the EORTC QLQ BN20 questionnaire

    Time frame: 6 weeks postoperatively

  14. Quality of life at 3 months (EORTC QLQ BN20)

    Quality of life as assessed by the EORTC QLQ BN20 questionnaire

    Time frame: 3 months postoperatively

  15. Quality of life at 6 months (EORTC QLQ BN20)

    Quality of life as assessed by the EORTC QLQ BN20 questionnaire

    Time frame: 6 months postoperatively

  16. Quality of life at 6 weeks (EQ-5D)

    Quality of life as assessed by the EQ-5D questionnaire

    Time frame: 6 weeks postoperatively

  17. Quality of life at 3 months (EQ-5D)

    Quality of life as assessed by the EQ-5D questionnaire

    Time frame: 3 months postoperatively

  18. Quality of life at 6 months (EQ-5D)

    Quality of life as assessed by the EQ-5D questionnaire

    Time frame: 6 months postoperatively

07

Study locations

6 of 8 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jan 2027, 48 months after the start.

Of 85 non-industry observational studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's planned 48 months is below that.

Counting every sponsor, half of 100 studies reached it within 52 months; a quarter within 33 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2023
First posted
Feb 22, 2024
StartActual
Jan 1, 2023
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2028
Last update
Feb 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06273176
Responsible party
Jasper Gerritsen (MD PhD, Erasmus Medical Center) — Principal investigator
First posted
Feb 22, 2024
Start date
Jan 1, 2023
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Feb 22, 2024

Study contacts

Jasper Gerritsen, MD PhD
Contact
j.gerritsen@erasmusmc.nl
+31107036130
Arnaud Vincent, MD PhD
Contact
a.vincent@erasmusmc.nl
+31107034211
Jasper Gerritsen, MD PhD
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion